technologynetworks

Cerenis Reports Positive Results for Phase 1 Study of CER-001 for the Treatment of Cardiovascular Disease

Cerenis Therapeutics has announced the completion of a Phase 1 study of the Company's CER-001 investigational product candidate to treat patients with acute coronary syndromes. Results of the ...
Business Wire

Cerenis Therapeutics: First results of TARGET PHASE II study demonstrate the ability of CER-001, an HDL mimetic, to target tumor in patients with esophageal cancer

TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News: Cerenis Therapeutics (Paris:CEREN) (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated ...
technologynetworks

Cerenis Initiates Phase 2 Study of CER-001, in Patients with Acute Coronary Syndrome

Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and metabolic diseases, has announced the start of the Phase 2 ...
Business Wire

CERENIS Announces the Results of TANGO, a Phase III Clinical Study Evaluating CER-001 in Patients with HDL Deficiency

TOULOUSE, France & LAKELAND, Fla.--(BUSINESS WIRE)--Regulatory News: Cerenis Therapeutics (Paris:CEREN)(FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated ...
Yahoo Finance

Cerecin received US FDA clearance to study CER-0001 under an Investigational New Drug (IND) application for Infantile Spasms

A pilot study of CER-0001 in IS is ongoing in Australia and Singapore and due to complete enrollment in 1H 2023 DENVER and SINGAPORE, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Cerecin Inc., a clinical-stage ...